{
  "docId": "019de073-a4f9-77e5-8cbf-a98a0ec20f41",
  "docSlug": "527bf315fca9a14279ec523dc4665564",
  "documentTitle": "Athira Pharma | Results Presentation Deck | 11 slides",
  "authorId": "athira-pharma",
  "authorName": "Athira Pharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 11,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses a bulleted list to summarize clinical trial milestones and data-driven decision-making.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a4f9-77e5-8cbf-a98a0ec20f41/3",
  "deckHref": "/decks/019de073-a4f9-77e5-8cbf-a98a0ec20f41",
  "deckJsonHref": "/decks/019de073-a4f9-77e5-8cbf-a98a0ec20f41.json",
  "deckAnchorHref": "/decks/019de073-a4f9-77e5-8cbf-a98a0ec20f41#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "callout",
      "text": "INDEPENDENT UNBLINDED INTERIM ANALYSIS SUPPORTS POTENTIAL CLINICALLY MEANINGFUL ACTIVITY OF FOSGONIMETON WITHOUT BACKGROUND THERAPY AND MITIGATES PROGRAM RISK",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a54d69e-2c88-4076-a6f5-21d883174b3b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Phase 2 exploratory ACT-AD study results suggested congruent positive effects; Cognition (ADAS-Cog11); Function (ADCS-ADL23); Neurodegeneration (neurofilament light chain or NfL)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50294d9e-f45e-4b4e-93a4-6dc1b18e4bd7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "list",
      "text": "Data driven approach was used to determine best path forward to optimize ongoing Phase 2/3 LIFT-AD study in the same patient population as in ACT-AD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c87b23d-5705-47a7-b02d-d39e7e896a08",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "Analysis of ~100 patients supports potential clinically meaningful effects of cognition and function and informs the sample size required to power LIFT-AD; Enrollment target of <150 additional patients enables LIFT-AD to be well-powered for the primary endpoint; Enrollment completion target by mid 2023 with topline data in early 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b502f8b9-b66f-4f96-8d33-a27f8660ee3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "ADAS-Cog11, Alzheimer's Disease Assessment Scale-Cognitive Subscale; ADCS-ADL23, Alzheimer's Disease Cooperative Study-Activities of Daily Living; NfL, neurofilament light chain.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37630600-df24-4f59-901e-de043164e502",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase 2/3 LIFT-AD Study Advances",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06d92859-41e0-4572-a6ad-4c5a2e75427a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 3,
      "from": 2,
      "beatId": "fa2c27bc-ebb6-4ff4-b2b4-2a4c0a80b0f4",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Current treatments have limitations, new therapies are needed",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 3,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "fdab6818-6721-40ae-8f52-56294433f949",
      "evidence": "Emphasis on current limitations and need for new therapies",
      "position": 0,
      "objective": "What is the cost of not developing new therapies for Alzheimer's disease?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}